Home › Funds › Neumann Advisory Hong Kong Ltd › SVA

Neumann Advisory Hong Kong Ltd position in SVA

Sinovac Biotech Ltd.

Neumann Advisory Hong Kong Ltd reported holding 315,586 shares of SVA (Sinovac Biotech Ltd.) in its Q3 2026 13F filing — a position valued at US$2.0M, representing 0.65% of its reported portfolio and ranking #4 among its reported holdings. Neumann Advisory Hong Kong Ltd has disclosed SVA holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)315.59K sh
Reported value held$2.04M
Portfolio Weight0.65%
First reportedQ3 2023
Last changeHold
Updated2026-10-09

Last updated: 2026-10-09 · Source: SEC EDGAR Form 13F-HR

How Neumann Advisory Hong Kong Ltd's SVA position evolved

Neumann Advisory Hong Kong Ltd first disclosed a stake in SVA in Q3 2023 at 315,586 shares (US$2.0M). Across 13 filings, Neumann Advisory Hong Kong Ltd held the position steady without any share-count change. The most recent filing (Q3 2026) shows 315,586 shares valued at US$2.0M.

Quarter by quarter

QuarterSharesValueChange
Q3 2023 315.59K $2.04M New
Q4 2023 315.59K $2.04M Hold
Q1 2024 315.59K $2.04M Hold
Q2 2024 315.59K $2.04M Hold
Q3 2024 315.59K $2.04M Hold
Q4 2024 315.59K $2.04M Hold
Q1 2025 315.59K $2.04M Hold
Q2 2025 315.59K $2.04M Hold
Q3 2025 315.59K $2.04M Hold
Q4 2025 315.59K $2.04M Hold
Q1 2026 315.59K $2.04M Hold
Q2 2026 315.59K $2.04M Hold
Q3 2026 315.59K $2.04M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About SVA and 13F data

SVA (Sinovac Biotech Ltd.) is a company whose sector is not yet classified in our data. 8 other funds we track also report a position in SVA — the largest reported positions include ORBIMED ADVISORS LLC (US$184.5M), Vivo Capital, LLC (US$38.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding SVA

All SVA fund holders →

FAQ

How long has Neumann Advisory Hong Kong Ltd held SVA?

Neumann Advisory Hong Kong Ltd has disclosed SVA holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is Neumann Advisory Hong Kong Ltd's current position in SVA?

As of Q3 2026, Neumann Advisory Hong Kong Ltd holds 315.59K shares of SVA (Sinovac Biotech Ltd.), valued at $2.04M, representing 0.65% of its reported portfolio and ranking #4.

Has Neumann Advisory Hong Kong Ltd been buying or selling SVA?

In the latest 13F filing (Q3 2026), Neumann Advisory Hong Kong Ltd held unchanged its position in SVA.

Which other funds hold SVA?

Other major institutional holders of SVA include ORBIMED ADVISORS LLC, Vivo Capital, LLC, among 8 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.